Astra AB

Astra AB
source
Name	Astra AB
Foundation	11 April 1913 in Södertälje, Sweden
Founder	Johan Edvard Lundström
Defunct	0 1999
Fate	Merged with Zeneca Group to form AstraZeneca
Industry	Pharmaceuticals
Key people	Håkan Mogren (last CEO)
Products	Pharmaceuticals, Agrochemicals
Num employees	30,000+ (1998)
Location	Södertälje, Sweden

Contents

History
Products
Operations
Corporate affairs
See also

Astra AB. A pioneering Swedish pharmaceutical company, it was a cornerstone of the nation's industrial and scientific landscape for most of the 20th century. Founded in 1913, it grew from a domestic manufacturer into a significant international player, renowned for its research in areas like gastrointestinal and cardiovascular therapeutics. Its legacy is cemented by its 1999 merger with the British company Zeneca Group, forming the global biopharmaceutical giant AstraZeneca.

History

The company was established on 11 April 1913 in Södertälje by Johan Edvard Lundström, initially focusing on importing and selling pharmaceuticals. A pivotal early acquisition was the Södertälje-based drug manufacturer Apotekarnes Droghandel, which provided crucial manufacturing capabilities. Throughout the mid-20th century, Astra expanded its research footprint, establishing the Astra Research Laboratories and making strategic acquisitions like Hässle in 1947, which bolstered its cardiovascular research. A major breakthrough came with the development of the beta blocker Atenolol in the 1960s, followed by the global success of the proton-pump inhibitor Omeprazole (marketed as Losec) in the late 1980s, which became the world's best-selling medicine for several years. This period of intense innovation and international expansion, including significant growth in the United States and Japan, set the stage for its transformative merger.

Products

Astra's portfolio was defined by several blockbuster medicines developed through intensive in-house research. Its most famous product was Omeprazole, a revolutionary treatment for peptic ulcer disease and gastroesophageal reflux disease that dominated global sales. In cardiology, the company was known for Atenolol and later Metoprolol, key agents in managing hypertension and angina pectoris. The respiratory division produced Budesonide, a corticosteroid used in asthma and allergic rhinitis, marketed in collaboration with companies like Draco (later part of the Lund University-linked Astra Draco). Other significant products included the local anesthetic Bupivacaine and various agrochemicals and veterinary medicines, reflecting its diversified life science operations.

Operations

The company's operations were centered on its extensive research and manufacturing complex in Södertälje, which served as its global headquarters. Internationally, Astra maintained substantial subsidiaries, with Astra USA being critical for its commercial success in the North American market. Major production facilities were also located in France, the United Kingdom, and Canada. Its research was highly collaborative, involving partnerships with academic institutions like the University of Gothenburg and the Karolinska Institute, as well as with other pharmaceutical entities. The operational structure was divided into distinct business areas, including Pharmaceuticals, Agrochemicals (managed through Astra Agro), and a dedicated Animal Health unit, allowing focused development and marketing across different sectors.

Corporate affairs

In its final decades, Astra was led by CEOs such as Håkan Mogren, who steered the company toward a more globalized strategy. The board included prominent figures from Swedish industry and academia. A significant corporate evolution was the 1993 demerger of its specialty chemicals and biotech assets, which were formed into the separate listed company Pharmacia (later part of Pfizer). This refocused Astra purely on pharmaceuticals. The defining corporate event was the 1999 merger of equals with the Anglo-Swedish company Zeneca Group, which had been formed from the bioscience division of Imperial Chemical Industries. This deal, orchestrated to enhance global scale and research pipelines, created AstraZeneca, with combined headquarters in London and major R&D sites remaining in Södertälje and Cambridge.

History

Products

Operations

Corporate affairs

See also